OpenAI-backed start-up Chai Discovery has raised $70mn, valuing the group at about $550mn, as investors bet on the potential for artificial intelligence to speed up drug discovery and tackle disease.

First, data and digital business services company, has been recognised as a Major Contender in Everest Group’s Life Sciences Digital Services PEAK Matrix® Assessment 2025. This recognition reflects ...

In this week’s edition of InnovationRx, we look at a biotech entrepreneur treating a rare genetic disease, new tech aimed at ...

Second quarter earnings season is in full swing, and the results have been largely positive so far, with more positive ...

Second quarter earnings season is in full swing, and the results have been largely positive so far, with more positive ...

Second quarter earnings season is in full swing, and the results have been largely positive so far, with more positive ...

The RESONATE-2 trial reveals ibrutinib's long-term efficacy and safety in treating CLL/SLL, especially for high-risk patients ...